EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase I)Open Access · CC BY-NC 4.0

ON-01, an engineered recombinant oncolytic herpes simplex virus type-1, in recurrent glioma: A single-arm, phase 1/2 study

Wei Zeng, Peiwen Wang, Sheng Fang, Siqi Ge, Weifeng Jia, Shirong Peng, Mengyang Wang, Xiaoyang Qin, Wenxin Zhang, Jiajia Gao, Xiaodong Su, Guiqiang Yuan und 11 weitere

Neuro-Oncology · 2026

DOI: 10.1093/neuonc/noag005 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Neuro-Oncology, 2026. Verfasst von Wei Zeng und 22 weiteren Autor:innen. Beteiligte Einrichtung: Brain Tumor Research Center, Beijing Neurosurgical Institute, Capital Medical University, Beijing, People's Republic of China. Hauptthemen laut MEDLINE: Oncolytic Virotherapy, Glioma, Brain Neoplasms, Herpesvirus 1, Human. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Capital's Funds for Health Improvement and Research, Capital’s Funds for Health Improvement and Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The prognosis of patients with recurrent WHO grade 4 glioma is poor, particularly in glioblastoma, which has a median survival of approximately 6 months and no effective treatment options. We evaluated the short-term (28-day) safety and efficacy of ON-01, an engineered recombinant oncolytic herpes simplex virus type-1, in patients with recurrent WHO grade 4 glioma.

Methods

In this single-arm, phase 1/2 clinical trial, eligible patients received intratumoral injections of ON-01 under stereotactic guidance. The primary endpoint was to assess the short-term safety profile of ON-01 treatment. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and the 2-year OS rate. An exploratory objective was to identify tumor-related biomarkers predictive of treatment efficacy.

Results

Of the 30 patients treated with ON-01, 13 (43.3%) were male, and the median age was 50.0 years (range, 22-75). A total of 36 grade 1, 12 grade 2, and 2 grade 3 adverse events were reported. Among all treated patients, the median OS was 12.0 months (95% CI, 10.1-13.9), median PFS was 3.0 months (95% CI, 1.7-4.3), and 2-year OS rate was 27.7% (95% CI, 12.6%-45.0%). Seven patients with recurrent multifocal gliomas demonstrated regression of non-injection site lesions following ON-01 therapy. Furthermore, patients with elevated expression of herpesvirus entry mediator exhibited significantly prolonged survival (P = .015).

Conclusions

Intratumoral infusion of ON-01 appeared safe and demonstrated efficacy in patients with recurrent malignant glioma, with no evidence of neurotoxicity. The therapeutic response to ON-01 may be associated with HVEM expression levels.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oncolytic VirotherapyGliomaBrain NeoplasmsHerpesvirus 1, HumanNeoplasm Recurrence, LocalOncolytic VirusesHumansMaleFemaleAdultMiddle AgedAgedYoung AdultSurvival RatePrognosisFollow-Up Studies

Stichwörter der Autor:innen

herpes simplex virusoncolytic virotherapyrecurrent gliomasingle-arm trial

Autor:innen und Institutionen

  • Brain Tumor Research Center, Beijing Neurosurgical Institute, Capital Medical University, Beijing, People's Republic of China.
  • Department of Neurosurgery, Capital Medical University Electric Power Teaching Hospital/State Grid Beijing Electric Power Hospital, Beijing, People's Republic of China.
  • Beijing Laboratory of Biomedical Materials, Beijing, People's Republic of China.
  • Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, People's Republic of China.
  • Department of Neuroepidemiology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, People's Republic of China.
  • Department of Pathology, Capital Medical University Electric Power Teaching Hospital/State Grid Beijing Electric Power Hospital, Beijing, China.

Förderung

  • Capital's Funds for Health Improvement and Research
  • Capital’s Funds for Health Improvement and Research

Zitieren

APA

Zeng, W., Wang, P., Fang, S., Ge, S., Jia, W., Peng, S., Wang, M., Qin, X., Zhang, W., Gao, J., Su, X., Yuan, G., Wu, J., Liu, Y., Wang, Y., Lu, H., Mu, R., Wu, F., Chang, Q., …, & Liu, F. (2026). ON-01, an engineered recombinant oncolytic herpes simplex virus type-1, in recurrent glioma: A single-arm, phase 1/2 study. Neuro-Oncology. https://doi.org/10.1093/neuonc/noag005

Vancouver

Zeng W, Wang P, Fang S, Ge S, Jia W, Peng S, et al. ON-01, an engineered recombinant oncolytic herpes simplex virus type-1, in recurrent glioma: A single-arm, phase 1/2 study. Neuro-Oncology. 2026. doi:10.1093/neuonc/noag005

BibTeX
@article{Zeng2026,
  author = {Zeng, Wei and Wang, Peiwen and Fang, Sheng and Ge, Siqi and Jia, Weifeng and Peng, Shirong and Wang, Mengyang and Qin, Xiaoyang and Zhang, Wenxin and Gao, Jiajia and Su, Xiaodong and Yuan, Guiqiang and Wu, Jiankun and Liu, Yida and Wang, Youwen and Lu, Huacong and Mu, Ran and Wu, Fang and Chang, Qing and Jin, Guishan and Meng, Fangang and Zhang, Junwen and Liu, Fusheng},
  title = {ON-01, an engineered recombinant oncolytic herpes simplex virus type-1, in recurrent glioma: A single-arm, phase 1/2 study},
  journal = {Neuro-Oncology},
  year = {2026},
  doi = {10.1093/neuonc/noag005}
}
Kostenlos starten →